4.7 Article

Cardiovascular Effects of Exposure to Cigarette Smoke and Electronic Cigarettes Clinical Perspectives From the Prevention of Cardiovascular Disease Section Leadership Council and Early Career Councils of the American College of Cardiology

期刊

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 66, 期 12, 页码 1378-1391

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2015.07.037

关键词

atherogenesis; genetic and epigenetic effects; smoke-free legislation; thrombosis; tobacco cessation

资金

  1. Eli Lilly and Company
  2. Daiichi-Sankyo
  3. Bristol-Myers Squibb
  4. Pfizer
  5. Abbott Vascular
  6. Medtronic

向作者/读者索取更多资源

Cardiovascular morbidity and mortality as a result of inhaled tobacco products continues to be a global healthcare crisis, particularly in low- and middle-income nations lacking the infrastructure to develop and implement effective public health policies limiting tobacco use. Following initiation of public awareness campaigns 50 years ago in the United States, considerable success has been achieved in reducing the prevalence of cigarette smoking and exposure to secondhand smoke. However, there has been a slowing of cessation rates in the United States during recent years, possibly caused by high residual addiction or fatigue from cessation messaging. Furthermore, tobacco products have continued to evolve faster than the scientific understanding of their biological effects. This review considers selected updates on the genetics and epigenetics of smoking behavior and associated cardiovascular risk, mechanisms of atherogenesis and thrombosis, clinical effects of smoking and benefits of cessation, and potential impact of electronic cigarettes on cardiovascular health. (C) 2015 by the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据